Since then, CCR7 has been suggested as a biomarker for lymph node metastasis [2,22], but, unlike CXCR4, few potential therapies have been developed [23,24]. This evidence concerns the gene CXCR4 and metastatic malignant neoplasm in the lymph nodes.